Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
LMY-920 / Luminary Therap
LMY-920-001, NCT05312801: Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma	Recruiting	1	20	US	BAFF CAR-T, LMY-920	Luminary Therapeutics, Case Comprehensive Cancer Center	Lymphoma, Non-Hodgkin Lymphoma, B-Cell	05/25	09/25
LMY-920-002, NCT05546723: LMY-920 for Treatment of Relapsed or Refractory Myeloma	Recruiting	1	30	US	Autologous CAR-T cell therapy expressing the BAFF-ligand.	Luminary Therapeutics, The Cleveland Clinic, Case Western Reserve University	Multiple Myeloma, Refractory, Multiple Myeloma in Relapse	07/25	10/25
LMY-920-003, NCT06340750: BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus	Not yet recruiting	1	18	US	LMY-920, BAFF CAR T	Luminary Therapeutics, Nationwide Children	Systemic Lupus Erythematosus	01/26	06/26